Intellia Therapeutics NTLA Share of other comprehensive (loss) income from Brookfield Asset Management ULC
Share of other comprehensive (loss) income from Brookfield Asset Management ULC at other companies
Other financials
Where this comes from
Reported directly by Intellia Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OciEquityMethodInvestmentAfterTaxParent.
The official record: Intellia Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Intellia Therapeutics's share of other comprehensive (loss) income from brookfield asset management ulc.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Intellia Therapeutics's share of other comprehensive (loss) income from brookfield asset management ULC?
- Intellia Therapeutics (NTLA) reported share of other comprehensive (loss) income from brookfield asset management ULC of -$0 in Q4 2025.
- What is the long-term trend for Intellia Therapeutics's share of other comprehensive (loss) income from brookfield asset management ULC?
- Over 3 years (2022 to 2025), Intellia Therapeutics's share of other comprehensive (loss) income from brookfield asset management ULC has grown at a -100.0% compound annual growth rate (CAGR), from -$3.19M to $0.
- What does share of other comprehensive (loss) income from brookfield asset management ULC mean?
- This metric captures the company's proportional share of other comprehensive income or loss generated by entities accounted for under the equity method. It reflects unrealized gains or losses, such as foreign currency translation adjustments or changes in the fair value of available-for-sale securities, attributable to these investments. It is a key indicator of the performance and volatility of the company's strategic equity holdings outside of core operations.